Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. more
Time Frame | GMAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.69% | -2.12% | -3% |
1-Month Return | -0.68% | -3.42% | -0.73% |
3-Month Return | -20.45% | -11.13% | 2.87% |
6-Month Return | -21.52% | -5.74% | 7.17% |
1-Year Return | -33.54% | 3.97% | 25.31% |
3-Year Return | -47.7% | 1.05% | 28.38% |
5-Year Return | -6.41% | 34.37% | 81.89% |
10-Year Return | 238.61% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.37B | 10.11B | 8.48B | 14.60B | 16.47B | [{"date":"2019-12-31","value":32.57,"profit":true},{"date":"2020-12-31","value":61.38,"profit":true},{"date":"2021-12-31","value":51.49,"profit":true},{"date":"2022-12-31","value":88.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | - | - | 226.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 5.37B | 10.11B | 8.48B | 14.60B | 16.25B | [{"date":"2019-12-31","value":33.03,"profit":true},{"date":"2020-12-31","value":62.23,"profit":true},{"date":"2021-12-31","value":52.2,"profit":true},{"date":"2022-12-31","value":89.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 98.63% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.63,"profit":true}] |
Operating Expenses | 2.73B | 3.80B | 5.46B | 8.24B | 10.93B | [{"date":"2019-12-31","value":24.97,"profit":true},{"date":"2020-12-31","value":34.76,"profit":true},{"date":"2021-12-31","value":50,"profit":true},{"date":"2022-12-31","value":75.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 2.64B | 6.31B | 3.02B | 6.36B | 5.32B | [{"date":"2019-12-31","value":41.5,"profit":true},{"date":"2020-12-31","value":99.31,"profit":true},{"date":"2021-12-31","value":47.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.7,"profit":true}] |
Total Non-Operating Income/Expense | 555.00M | (235.00M) | 1.15B | 1.07B | 1.23B | [{"date":"2019-12-31","value":45.2,"profit":true},{"date":"2020-12-31","value":-19.14,"profit":false},{"date":"2021-12-31","value":93.57,"profit":true},{"date":"2022-12-31","value":87.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 2.86B | 5.90B | 3.98B | 7.04B | 5.64B | [{"date":"2019-12-31","value":40.64,"profit":true},{"date":"2020-12-31","value":83.92,"profit":true},{"date":"2021-12-31","value":56.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.13,"profit":true}] |
Income Taxes | 693.00M | 1.15B | 975.00M | 1.51B | 1.28B | [{"date":"2019-12-31","value":45.8,"profit":true},{"date":"2020-12-31","value":75.74,"profit":true},{"date":"2021-12-31","value":64.44,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.93,"profit":true}] |
Income After Taxes | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | [{"date":"2019-12-31","value":39.22,"profit":true},{"date":"2020-12-31","value":86.16,"profit":true},{"date":"2021-12-31","value":54.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.81,"profit":true}] |
Income From Continuous Operations | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | [{"date":"2019-12-31","value":39.22,"profit":true},{"date":"2020-12-31","value":86.16,"profit":true},{"date":"2021-12-31","value":54.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.81,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 2.17B | 4.76B | 2.96B | 5.45B | 4.35B | [{"date":"2019-12-31","value":39.73,"profit":true},{"date":"2020-12-31","value":87.27,"profit":true},{"date":"2021-12-31","value":54.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":79.82,"profit":true}] |
EPS (Diluted) | 4.86 | 8.15 | 0.73 | 1.17 | 0.96 | [{"date":"2019-12-31","value":59.6,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":8.96,"profit":true},{"date":"2022-12-31","value":14.36,"profit":true},{"date":"2023-12-31","value":11.78,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
GMAB | |
---|---|
Cash Ratio | 3.78 |
Current Ratio | 5.17 |
Quick Ratio | 5.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GMAB | |
---|---|
ROA (LTM) | 10.95% |
ROE (LTM) | 14.92% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GMAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.20 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.80 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GMAB | |
---|---|
Trailing PE | 19.75 |
Forward PE | 13.79 |
P/S (TTM) | 0.64 |
P/B | 2.85 |
Price/FCF | 6 |
EV/R | 3.75 |
EV/Ebitda | 10.67 |
PEG | 0.70 |
Genmab AS (GMAB) share price today is $20.31
Yes, Indians can buy shares of Genmab AS (GMAB) on Vested. To buy Genmab AS from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Genmab AS (GMAB) via the Vested app. You can start investing in Genmab AS (GMAB) with a minimum investment of $1.
You can invest in shares of Genmab AS (GMAB) via Vested in three simple steps:
The 52-week high price of Genmab AS (GMAB) is $32.88. The 52-week low price of Genmab AS (GMAB) is $19.85.
The price-to-earnings (P/E) ratio of Genmab AS (GMAB) is 19.7451
The price-to-book (P/B) ratio of Genmab AS (GMAB) is 2.85
The dividend yield of Genmab AS (GMAB) is 0.00%
The market capitalization of Genmab AS (GMAB) is $12.79B
The stock symbol (or ticker) of Genmab AS is GMAB